HARMONY BIOSCIENCES HOLDINGS
HRMYNASDAQTrading Snapshot
- Day Range
- $39.07 – $39.93
- 52-Week Range
- $25.52 – $43.49
- Volume
- $1.83B
- Avg Volume
- $1.59B
- Shares Outstanding
- 57.9M
- Next Earnings
- Dec 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $868M
- Last Q Revenue
- $261M
- P/E Ratio
- 12.8
- P/S Ratio
- 2.4x
- EPS (TTM)
- $3.13
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.8%
Why Investors Own HRMY
- ✓High-growth profile — revenue up +53.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 35% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
HARMONY BIOSCIENCES HOLDINGS
HRMY
StockOtter · stockotter.spaceAbout HARMONY BIOSCIENCES HOLDINGS
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Insider Selling: Harmony Biosciences (NASDAQ:HRMY) Insider Sells $34,400.00 in Stock
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) insider Kumar Budur sold 800 shares of the firm's stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $43
Kumar Budur Sells 1,800 Shares of Harmony Biosciences (NASDAQ:HRMY) Stock
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) insider Kumar Budur sold 1,800 shares of the business's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $
Sonoma Pharmaceuticals (NASDAQ:SNOA) & Harmony Biosciences (NASDAQ:HRMY) Critical Analysis
Harmony Biosciences (NASDAQ: HRMY - Get Free Report) and Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based o
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
Harmony Biosciences (HRMY) reported earnings 30 days ago. What's next for the stock?
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company's investigation of EPX-100 (clemizole hydrochl
Canada Pension Plan Investment Board Takes $1.21 Million Position in Harmony Biosciences Holdings, Inc. $HRMY
Canada Pension Plan Investment Board acquired a new position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) in the undefined quarter, according to its most recent disclosure with the SEC. The fund acquire